Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Gastroenterology  |  Nephrology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Nephropathy Clinical Trials

A listing of Nephropathy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (31) clinical trials

The Rogosin Institute is conducting a clinical research study to assess the safety and efficacy of Velcade® to treat severe IgA nephropathy. Velcade® is FDA-approved for the treatment of multiple myeloma, not for IgA nephropathy, but it may act on non-cancerous normal plasma cells that produce abnormal antibody proteins. IgA ...


Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension

It is reported that the risk of a cardiovascular event occurring is 1.78 times higher in patients with diabetic nephropathy (DN) than in patients without DN. It is also reported that angiotensin II receptor blockade (ARB) prevents the progression of DN in diabetic patients with early phase nephropathy beyond its ...


Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion

This study is design to compare two different strategies aiming to lessen the degree of the ongoing process of allograft injury either by removing tacrolimus from the maintenance immunosuppressive protocol or by reducing tacrolimus dose. The primary goal is to assess the change in renal function at 6 and 12 ...


Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis in the world. Its estimated frequency is at least 2.5 cases per year per 100,000 adults. The glomerulopathy usually progressed slowly leading to end stage renal disease (ESRD). ESRD developed in 20%-40% of patients after 20 years. Given its complex ...


Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan

This is a prospective, multi-center, randomized, open-label, parallel-arm controlled study, for which a total of 216 patients with type 2 diabetic nephropathy (Stage II-IV) will be enrolled. The subjects will be randomized to three groups in 1:1:1 ratio. One group receive Alfacalcidol 0.25ug/day and Irbesartan 150mg/day for 16 consecutive weeks. ...


Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes

Background: SGLT2 inhibitors are the first antiglycaemic drugs with a direct renal action. A part from reducing blood glucose, systemic blood pressure and albuminuria are decreased, while natriuresis is increased. Previous research into urinary peptide patterns (proteomics) has revealed that patients in risk of progressive renal disease display a "risk ...


ISCHEMIA-Chronic Kidney Disease Trial

BACKGROUND Among patients with advanced CKD, cardiovascular disease is the leading cause of death,15-30 times higher than the age-adjusted cardiovascular mortality rate in the general population. The projected 4-year mortality is >50% in patients with advanced CKD and is worse than that for patients in the general population who have ...


Myfortic for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study

This is a prospective, open-label, randomized study in which patients who present for the first time with a clinical diagnosis of idiopathic MCNS proven on renal biopsy will be assigned to either conventional standard-dose prednisolone monotherapy or myfortic combined with low-dose prednisolone treatment for 6 months. Clinical response and relapse ...


The Effect of the Forced Diuresis With Matched Hydration in Reducing Acute Kidney Injury During TAVI

Reducing Acute Kidney Injury in TAVI Patients (REDUCE trial) The Effect of the Forced Diuresis With Matched Hydration in Reducing Acute Kidney Injury During Transcatheter Aortic Valve Implantation (TAVI) Interventional Cardiology, Department of Cardiology Tel Aviv Medical Center Tel Aviv Sackler Faculty of Medicine, Tel Aviv University Introduction Hypothesis: RenalGuard ...